Designed to support patients prescribed IDACIO (adalimumab)

KabiCare is only for patients who have been prescribed IDACIO. By registering, you will have access to information and resources which may help you:

  • Increase your knowledge about IDACIO
  • Better understand your condition
  • Manage the emotional impact your condition may have on your daily life

You will need the unique code provided on the access card in your starter pack.

KabiCare is for people who have been prescribed IDACIO

IDACIO is the Fresenius Kabi brand name of a biologic medicine called adalimumab.1 IDACIO is used to help treat some chronic conditions that happen when the body's immune system wrongly attacks itself. This is known as an autoimmune disease.2

There are more than 80 types of autoimmune disorder.3 They occur when the immune cells in our body that usually fight ‘foreign invaders’ like bacteria and viruses and start to attack the body’s own cells by mistake.2 This causes inflammation and damage.Autoimmune diseases can affect different areas of the body, for example the joints, the skin or the gut.2

Biologic medicines can be prescribed by a specialist doctor under specific circumstances for certain types of autoimmune condition including:1

  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Plaque psoriasis
  • Psoriatic arthritis
  • Crohn's disease and ulcerative colitis
  • Non-infectious uveitis
  • Hidradenitis suppurativa

What are biologics and biosimilars?

Biologic medicines are large, complex molecule medicines that are made using living cells.4 They may be used to treat a range of long-term illnesses, including those caused by autoimmune disease.4

The European Commission states "a biosimilar medicine is developed to be highly similar to an existing biological medicine".4 When a biosimilar is developed, the original biological medicine is known as ‘the reference medicine’.4 Biosimilars can be developed once the reference medicine has been available to patients for a number of years.4 During its development, a biosimilar is studied in a number of different ways, as shown below.5

3-step diagram describing how biosimilar medicines are tested during development


For more details, register with KabiCare.

You will need the unique code provided on the access card in your starter pack.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard (for UK residents) or see http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.